Narrow search
Showing 71 - 80 of 50,672
Cover Image
Development and description of GETT: a Genetic testing Evidence Tracking Tool
School of Biomedical Sciences
Background: The completion of the Human Genome Project has increased the pace of discovery of genetic markers for disease. Despite tremendous efforts in fundamental research, clinical applications still lag behind expectations, partly due to the lack of effective tools to systematically search...
Persistent link: https://www.econbiz.de/10009479418
Cover Image
Essential notion of the health economic evaluation: Definition
Botchkarev, Alexei - In: Atlantic Review of Economics 2 (2016)
Background: Economic evaluation (EE) is a dynamically advancing knowledge area of health economics. It has been conceived to provide evidence for allocating scarce resources to gain the best value for money. The problem of efficiency of investments becomes even more crucial with advances in...
Persistent link: https://www.econbiz.de/10011966823
Cover Image
Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view
Giuliani, Giovanni; Chassagnol, Frederic; Traub, David; … - In: Health Economics Review 8 (2018) 24, pp. 1-11
. We reviewed recent appraisals of a pharmaceutical manufacturer in three major European markets (France; Italy; Germany … current management of the condition (unmet need, Italy), the regulatory status (Orphan Designation, Germany), as well as … medicines was 63 (Germany), 459 (Italy), and 557 days (France). Conclusions: The clinical domains of the EUnetHTA framework are …
Persistent link: https://www.econbiz.de/10012010780
Cover Image
Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer
Bilekova, Beata Kiselova; Gavurova, Beata; Rogalewicz, … - In: Health Economics Review 8 (2018) 27, pp. 1-13
Background: Health technology assessment (HTA) is currently one of the major challenges in assessing medical innovations and healthcare systems. In Europe, the European Network for Health Technology Assessment (EUnetHTA) has been aspiring to develop and implement standards for international...
Persistent link: https://www.econbiz.de/10012010783
Cover Image
A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe
Lee, Dawn C.; Gladwell, Daniel; Hatswell, Anthony J.; … - In: Health Economics Review 4 (2014) 6, pp. 1-15
In the majority of children and adolescents with epilepsy, optimal drug therapy adequately controls their condition. However, among the remaining patients who are still uncontrolled despite mono-, bi- or tri-therapy with chronic anti-epileptic treatment, a rescue medication is required. In...
Persistent link: https://www.econbiz.de/10011599807
Cover Image
The Role of decision-analytic modelling in German health technology assessments
Kuhlmann, Alexander; Treskova, Marina; Braun, Sebastian; … - In: Health Economics Review 5 (2015) 7, pp. 1-7
Background: Decision-analytic modelling (DAM) has become a widespread method in health technology assessments (HTA), but the extent to which modelling is used differs among international HTA institutions. In Germany, the use of DAM is optional within HTAs of the German Institute of Medical...
Persistent link: https://www.econbiz.de/10011599818
Cover Image
Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions
Walker, Simon; Sculpher, Mark; Claxton, Karl; Palmer, Steve - Centre for Health Economics, Department of Economics … - 2012
Context Until recently, purchasers’ options regarding whether to pay for the use of technologies have been binary in nature: a treatment is covered or not covered. However, policies have emerged which expand the options - for example, linking coverage to evidence development, an option...
Persistent link: https://www.econbiz.de/10011133794
Cover Image
The influence of cost-effectiveness and other factors on NICE decisions
Dakin, Helen; Devlin, Nancy; Feng, Yan; Rice, Nigel; … - Centre for Health Economics, Department of Economics … - 2013
Background: The National Institute for Health and Care Excellence (NICE) emphasises that cost-effectiveness is not the only consideration in health technology appraisal and is increasingly explicit about other factors considered relevant. Observing NICE decisions and the evidence considered in...
Persistent link: https://www.econbiz.de/10011133797
Cover Image
The price of pharmaceutical products in Italy. On some recent trends
Fabio, Pammolli; Gianluca, Baio; Armando, Rungi - In: Mercato Concorrenza Regole (2014) 2, pp. 265-282
Questo contributo analizza e commenta alcune tendenze recenti nella regolazione dei prezzi delle specialità medicinali. Il lavoro si concentra sulla crescente difficoltà nel riconciliare le richieste di prezzo per i farmaci maggiormente innovativi, sviluppati dalle imprese a valle di attività...
Persistent link: https://www.econbiz.de/10011158015
Cover Image
Is There a 'Continental' View of Health Economics Evaluation ?
Le Pen, Claude - Université Paris-Dauphine (Paris IX) - 2009
Persistent link: https://www.econbiz.de/10011166575